Autoimmune Cytopenias Occurring after Treatment with Chemoimmunotherapy for Non-Hodgkin Lymphomas

Oka, Shiro; Nohgawa, Masaharu

doi:10.1159/000495600

Cited by 3 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As regards autoimmune manifestations diagnosed after lymphoma onset, they could be the expression of an impaired immune-response caused by the lymphoma, and their impact on prognosis could be related to treatment-tolerability, especially in the case of autoimmune cytopenias. In this regard, recently, a study demonstrated in NHLs a relationship between imbalances in helper/suppressor T-cell populations and the development of auto-antibody production after chemotherapies [39].…”

Section: Discussionmentioning

confidence: 99%

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

Masciopinto

Dell’Olio

Robertis

et al. 2020

JCM

View full text Add to dashboard Cite

The connection between autoimmune disease (AID) and lymphoproliferative disorders is a complex bidirectional relationship that has long been a focus of attention by researchers and physicians. Although advances in pathobiology knowledge have ascertained an AID role in the development of lymphoproliferative diseases developing, results about AID influence on the prognosis of lymphoma are discordant. In this review, we collect the most relevant literature debating a direct or indirect link between immune-mediated diseases and lymphoma prognosis. We also consider the molecular, genetic, and microenvironmental factors involved in the pathobiology of these diseases in order to gain a deeper understanding of the nature of this link.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

Masciopinto

Dell’Olio

Robertis

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…AIC may occur after treatment with agents other than chemoimmunotherapy, BTK or BCL2 inhibitors as described above. 81 Stimulation of the immune system may have detrimental effects on a preexisting autoimmune condition. In most studies with immunomodulators or immune-checkpoint inhibitors, patients with autoimmune diseases were excluded.…”

Section: Autoimmune Complications Of Antilymphoma Treatmentmentioning

confidence: 99%

“…AICs may occur after treatment with agents other than chemoimmunotherapy or BTK or BCL2 inhibitors, as described earlier. 79 …”

Section: Autoimmune Complications Of Antilymphoma Treatmentsmentioning

confidence: 99%

How I manage autoimmune cytopenias in patients with lymphoid cancer

Porpaczy¹,

Jaeger

2022

Blood

View full text Add to dashboard Cite

Autoimmune conditions can occur at any temporary relationship with malignant lymphomas. In many instances, treatment at diagnosis is not required, but symptomatic autoimmune conditions represent an indication for treatment particularly in chronic lymphoproliferative diseases. Treatment is selected depending on the predominant condition - autoimmune disease (immunosuppression) or lymphoma (anti-lymphoma therapy). Steroids as well as anti-CD20 antibodies are effective against both and may suppress the autoimmune complication for a prolonged period. Efficacy of B-cell receptor inhibitors has provided us with novel insights into the pathophysiology of antibody-producing B-cells. Screening for underlying autoimmune conditions is part of the lymphoma work-up since other drugs like immunomodulators or checkpoint inhibitors should be avoided or used with caution. Here we discuss diagnostic challenges and treatment approaches for different situations involving lymphomas and autoimmune cytopenias.

show abstract

Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia

Zhou¹,

Wu²,

Peng³

et al. 2020

Medicine

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) can co-exist with autoimmune hemolytic anemia (AIHA), a phenomenon known as AIHA-associated NHL (AIHA/NHL). However, few studies have reported AIHA/NHL incidence or its clinical characteristics. We conducted a retrospective analysis of 20 AIHA/NHL patients treated at our hospital from 2009 to 2018. AIHA/NHL was presented by only 0.91% of the NHL and 9.8% of the AIHA patients. In addition, AIHA occurred most frequently with angioimmunoblastic T-cell lymphoma (AITL) (7.31%), followed by marginal zone B-cell lymphoma (MZBL) (6.25%), B-cell lymphoma-unclassified (BCL-U) (4.25%), chronic lymphocytic leukemia/small lymphocyte lymphoma (CLL/SLL) (2.50%), and mantle cell lymphoma (MCL) (2.30%). In addition to the CLL/SLL patients with impaired bone marrow, 66.7% of the AIHA/NHL patients had lymphoma bone marrow infiltration (LBMI), of which 4 patients presented LBMI in bone marrow smears (BMS) but not in bone marrow biopsy (BMB) and 6 were positive for BMB but not BMS. The 1-, 3- and 5-year survival rates of AIHA/NHL patients were 70%, 30% and 20%, respectively, and they responded poorly to chemotherapy. In conclusion, AIHA can co-exist with various NHLs and the defining clinical characteristic of AIHA/NHL is the high incidence of LBMI. However, both BMS and BMB should be performed to avoid missed diagnosis.

show abstract

Autoimmune Cytopenias Occurring after Treatment with Chemoimmunotherapy for Non-Hodgkin Lymphomas

Cited by 3 publications

References 7 publications

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

The Role of Autoimmune Diseases in the Prognosis of Lymphoma

How I manage autoimmune cytopenias in patients with lymphoid cancer

Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia

Contact Info

Product

Resources

About